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A commentary on
Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to
Stimulate Cytokine Release In Vitro
by Khan Mirzaei, M., Haileselassie, Y., Navis, M., Cooper, C., Sverremark-Ekström, E., and Nilsson,
A. S. (2016). Front. Microbiol. 7:437. doi: 10.3389/fmicb.2016.00437
In their recent paper, Khan Mirzaei et al. investigated the pro-inflammatory potential of
bacteriophages (KhanMirzaei et al., 2016). They addressed a crucial question linked to the safety of
phage therapy, especially when the administration of bacteriophages is anticipated to be performed
on highly reactive body compartments (e.g., the bloodstream by intravenous injection or the lung
alveolar area by nebulization).
Using peripheral blood mononuclear cells from healthy donors they measured the release of
three cytokines (TNF, IL-6, and IL-10) following incubation with four different bacteriophage
solutions. As routinely performed, the positive control consisted in lipopolysaccharide extract
(LPS) and the negative control in cell culture medium (low endotoxin controlled medium). When
using the highest amount of bacteriophages (109 PFU/well), the authors observed that most of
the solutions led to a significant increase in the acute pro-inflammatory cytokines (IL-6, TNF-α),
compared to the level obtained with the negative control.
Surprisingly, the four bacteriophages solutions elicited a very high release of pro-inflammatory
cytokines, with average values ranging from 0.25 to 1-fold the values obtained with the positive
LPS control. In particular, bacteriophage SU63 was found to be as potent as LPS to induce an IL-6
secretion with a value as high as 40,000 pg/mL.
Such results raise the question of the quality of the bacteriophage preparations in terms of
endotoxin level. Since a universally approved method for the preparation of bacteriophages for
human application (or animals, including those used in experimental phage therapy models) is still
lacking, we should make our best efforts to fully document the method used.
Here the authors followed a well-known protocol starting from polyethylene glycol precipitation
of a bacterial lysate followed by a cesium chloride (CsCl) ultracentrifugation step and most likely a
dialysis against a buffer which composition is not specified. No further purification step seems to
have been undertaken before these solutions were tested for their pro-inflammatory potential. We
believe and subsequently present supporting data that such a protocol is not sufficient to remove
endotoxin contamination from CsCl-purified bacteriophage solutions.
Dufour et al. Proinflammatory Signals? Check Purity First
In our laboratory, we use a different protocol based
on concentration/washing by ultrafiltration and two CsCl
ultracentrifugations (a step gradient followed by an isopycnic
gradient) (Henry et al., 2013). After the dialysis step, we perform
an affinity chromatography dedicated to endotoxin removal
(EndoTrap Blue, Hyglos, Germany). This last step, repeated 3 to 5
times, is easily carried out using commercially available columns
and can guarantee, in most cases, a very low level of endotoxin,
usually below 0.5 EU/mL.
When we measured the endotoxin level present in solutions
dialyzed following CsCl ultracentrifugations, we found them to
be quite high (see Figure 1 for 4 independent solutions). It
is only after the third passage through the endotoxin removal
column that low levels were reached. The use of such endotoxin
removal methods applied to bacteriophage solutions were, to our
knowledge, first reported in 2004 (Boratynski et al., 2004) and
are considered as a required step when producing bacteriophage
batches for clinical applications (Merabishvili et al., 2009) or
immunological studies (Majewska et al., 2015). In the absence of
such appropriate procedures, Cooper et al. (2014) have measured
a gigantic level of endotoxin (>1,000,000 EU/mL) in a cocktail
of bacteriophages prepared for nebulization and obtained from
FIGURE 1 | Endotoxin levels in four independent preparations of bacteriophage PAK-P1 infecting Pseudomonas aeruginosa (Henry et al., 2013).
Limulus amebocyte lysate-based assays (Endozyme rFC assay, Hyglos, Germany) were carried out before and after 1 to 5 passages of the solutions through a
specific endotoxin removal column (Endotrap blue, Hyglos, Germany). Before the specific endotoxin removal step, each bacterial lysate (500mL) was sterilized with
two in-line filters (pore sizes, 0.8 to 0.45 and 0.2 to 0.1 µm; Sartopore 300; Sartorius) and concentrated/washed with an ultrafiltration cassette (Vivaflow 200;
Sartorius). The concentrates were then ultracentrifuged twice on cesium chloride gradients and dialyzed against Tris buffer (10mM Tris, 150mM NaCl, pH7.5). Final
concentration ranged from 109 to 1011 pfu/mL. Similar results were observed with coliphages.
a crude lysate passed through a rudimentary 0.2 µm filter for
sterilization.
Therefore, only purified bacteriophage solutions showing
the lowest achievable endotoxin level (which may vary for
each bacteriophage preparation), should be used to perform
immunological tests. Otherwise, inaccurate conclusions could
be made by attributing to bacteriophages an effect that
originates from residual endotoxins (or other pro-inflammatory
molecules). Moreover, apart from endotoxin, which triggers
Toll-like receptor-4 (TLR-4), bacterial lysates may also contain
several pathogen-associated molecular patterns (PAMPs) able to
elicit a pro-inflammatory response, such as flagellin (sensed by
TLR-5), unmethylated CpG Oligodeoxynucleotide DNA (TLR-
9), lipoteichoic acid from Gram-positive bacteria (TLR-2) and
triacyl lipopeptides (TLR-1 with TLR-2) (Akira and Hemmi,
2003).
We can agree with the concluding remarks from Khan
Mirzaei et al., who suggest using ELISA assays to profile the
immune response induced by phage formulations in order
to provide a sensitive alternative to endotoxin assessment,
but only if such a profiling method is formerly bound to
an appropriate purification protocol dedicated to potent pro-
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inflammatory molecules removal. Unfortunately for patients,
when bacteria succumb to a viral attack, they do not
release a ready-to-use pharmaceutical grade bacteriophage
solution!
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